We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.newsWe've updated our Privacy Policy with additional info on research surveys, our browser extension, cookie management, and ad performance measurement. Questions? Email us any time at privacy@ground.news

Published 5 months ago • loading... • Updated 5 months ago

XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

South Korea's National Health Insurance Service approved reimbursement for XPOVIO® combined with bortezomib and dexamethasone to treat adult multiple myeloma patients after one prior therapy, effective March 1, 2026.
XPOVIO® has three approved indications in South Korea for multiple myeloma and diffuse large B-cell lymphoma, with two indications included in the national reimbursement scheme.
XPOVIO® is the world's first orally-available, selective XPO1 inhibitor and has national insurance coverage in five Asia-Pacific countries, including South Korea.

Insights by Ground AI

39 Articles

39 Articles

The Norfolk Daily News

+38 Reposted by 38 other sources

XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

SHANGHAI and HONG KONG, March 1, 2026

5 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources39

Leaning Left3Leaning Right6Center23Last Updated5 months agoBias Distribution

72% Center

Bias Distribution

72% of the sources are Center

72% Center

+18

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in Chicago, United States 5 months ago on Monday, March 2, 2026.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics